

Paxman Q3 (Review) - Softer sales than expected, but outlook remains strong

Redeye provides an update following Paxman's Q3 2025 report. The report came in slightly softer than expected; however, the investment case and strong outlook remain intact as we approach the pivotal year of 2026. In this update, we have made some downward revisions to our sales forecast, resulting in an updated fair value range.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Paxman Q3 \(Review\) - Softer sales than expected, but outlook remains strong](#)